Hepatitis C: How a Chronic Infection Became Curable

Hepatitis C became curable because two things happened at once. Direct-acting antiviral pills now clear the virus in more than 95 percent of people who complete a full 8-to-12-week course, and the field settled on a precise, durable definition of "cure" called sustained virologic response (SVR). Large studies then showed that reaching SVR tracks with lower death rates and fewer cases of liver cancer, which is why regulators accept it as proof that a treatment works. That same combination is why the U.S. Preventive Services Task Force moved in 2020 to recommend screening nearly every adult, not only those with obvious risk factors.

What "cure" actually measures

SVR means there is no detectable hepatitis C virus in the blood at a fixed point after treatment ends. Trials once measured it 24 weeks out (SVR24); the standard is now 12 weeks (SVR12), because the two results agree almost perfectly and SVR12 delivers an answer sooner. The reason SVR counts as a cure rather than a temporary remission is durability. Once a person reaches SVR, late relapse is rare. Long-term follow-up studies find that people who reach SVR almost never see the original virus return, which is what separates a cure from the temporary drops in viral load seen with earlier, less effective treatments. The virus is gone, and it stays gone.

That distinction shapes how the greater than 95 percent figure should be read. It describes the share of treated people whose virus is undetectable months after finishing a course. It is a measure of viral clearance, not a promise about the rest of a person's life.

From a lab number to a survival benefit

A cure endpoint is only meaningful if it predicts outcomes patients care about, and SVR earned that status through evidence. A 2012 study published in JAMA followed patients with chronic hepatitis C and advanced liver scarring and found that those who achieved SVR had substantially lower all-cause mortality than those who did not. That work came from the older interferon era, when cures were harder to reach and treatment was poorly tolerated. Broader analyses since then point the same direction: reaching SVR is associated with large reductions in liver-related death, in hepatocellular carcinoma (the most common liver cancer), and in the liver failure that leads to transplant.

Because SVR reliably forecasts these hard outcomes, it functions as a validated surrogate endpoint. Drug developers can run a trial that reads out in months using SVR12 rather than waiting years to count deaths or cancers, and regulators can evaluate a new antiviral on that basis. The AASLD-IDSA hepatitis C guidance, maintained jointly by the major U.S. liver and infectious-disease societies, describes current therapy as safe, short, and curative in most people, with SVR12 rates at or above 95 percent across treatment-naive adults, people with compensated cirrhosis, and those coinfected with HIV.

Why screening went universal

The screening logic follows directly from the cure. When treatment was long, toxic, and often failed, testing everyone was hard to justify. Now that a well-tolerated course cures the large majority in weeks, finding infections early carries clear value. In 2020 the USPSTF gave hepatitis C screening a Grade B recommendation for all adults aged 18 to 79, concluding with moderate certainty that screening this group offers substantial net benefit. The Task Force reached that conclusion partly because risk-based screening was missing cases and because infection rates had climbed among younger adults.

The mechanics are straightforward. Guidance recommends an initial antibody test, and if that is positive, a reflex HCV RNA test to confirm active infection. A positive antibody result signals past or present exposure, not necessarily an active infection, because a minority of people clear the virus on their own, and the RNA test settles the question. Screening is the entry point to care, since a person cannot be cured of an infection no one has detected.

For most adults this is a one-time test, with repeat testing for ongoing risk and testing during each pregnancy. This is educational information, not medical advice, and testing and treatment decisions belong with a qualified clinician.

Reading the "greater than 95 percent" claim honestly

Three caveats keep the number in perspective. First, cure rates vary by population. Treatment-naive patients without cirrhosis do better than those with advanced disease, so a headline figure is an average rather than a personal guarantee. Second, cure is not immunity. Clearing the virus does not prevent a new infection, so reinfection remains possible with repeat exposure. Third, cure does not erase risk that already accumulated. In people who had cirrhosis before treatment, the chance of liver cancer falls after SVR but does not reach zero, which is why guidelines call for continued cancer surveillance even after a documented cure.

None of this diminishes what happened. A disease that once smoldered for decades and drove a large share of liver transplants is now, for most people who are diagnosed and treated, a finite problem with a defined end. What made that possible was a measurable endpoint, validated against survival, that put both cure and universal screening on solid footing.